These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 29588589

  • 1. Hepatocellular carcinoma-targeted effect of configurations and groups of glycyrrhetinic acid by evaluation of its derivative-modified liposomes.
    Sun Y, Dai C, Yin M, Lu J, Hu H, Chen D.
    Int J Nanomedicine; 2018; 13():1621-1632. PubMed ID: 29588589
    [Abstract] [Full Text] [Related]

  • 2. Binding effect of fluorescence labeled glycyrrhetinic acid with GA receptors in hepatocellular carcinoma cells.
    Sun YQ, Dai CM, Zheng Y, Shi SD, Hu HY, Chen DW.
    Life Sci; 2017 Nov 01; 188():186-191. PubMed ID: 28768154
    [Abstract] [Full Text] [Related]

  • 3. Hepatocellular Carcinoma Targeting and Pharmacodynamics of Paclitaxel Nanoliposomes Modified by Glycyrrhetinic Acid and Ferric Tetroxide.
    Zhao L, Liang L, Guo M, Li M, Yu X, Wang Y, Wang Y.
    Curr Top Med Chem; 2021 Oct 05; 21(14):1268-1284. PubMed ID: 34620053
    [Abstract] [Full Text] [Related]

  • 4. Dual-Ligand-Functionalized Liposomes Based on Glycyrrhetinic Acid and cRGD for Hepatocellular Carcinoma Targeting and Therapy.
    Qiu M, Wang J, Bai J, Li X, Tian C, Liu Z, Zheng C, Clark AR, Cheng X, Liao X, Wu S, Lee RJ, Zhou X.
    Mol Pharm; 2023 Apr 03; 20(4):1951-1963. PubMed ID: 36952242
    [Abstract] [Full Text] [Related]

  • 5. The anti-tumor performance of docetaxel liposomes surface-modified with glycyrrhetinic acid.
    Li J, Xu H, Ke X, Tian J.
    J Drug Target; 2012 Jun 03; 20(5):467-73. PubMed ID: 22577855
    [Abstract] [Full Text] [Related]

  • 6. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S, Ren D, Wu X, Li M, Yu X, Nie X, Wang Y, Wang Y.
    Curr Top Med Chem; 2020 Jun 03; 20(27):2493-2505. PubMed ID: 32703132
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Construction of redox-sensitive liposomes modified by glycyrrhetinic acid and evaluation of anti-hepatocellular carcinoma activity.
    Hu J, Zheng Y, Wen Z, Fu H, Yang X, Ye X, Zhu S, Kang L, Li X, Yang X, Hu Y.
    Chem Phys Lipids; 2023 May 03; 252():105292. PubMed ID: 36931583
    [Abstract] [Full Text] [Related]

  • 14. Synthesis of glycyrrhetinic acid-modified liposomes to deliver Murrayafoline A for treatment of hepatocellular carcinoma.
    Dinh CT, Vu HT, Phan QTH, Nguyen LP, Tran TQ, Van Tran D, Quy NN, Pham DTN, Nguyen DT.
    J Mater Sci Mater Med; 2022 Oct 04; 33(10):72. PubMed ID: 36195780
    [Abstract] [Full Text] [Related]

  • 15. Anti-tumor therapy of glycyrrhetinic acid targeted liposome co-delivery of doxorubicin and berberine for hepatocellular carcinoma.
    Xu N, Wu J, Wang W, Sun S, Sun M, Bian Y, Zhang H, Liu S, Yu G.
    Drug Deliv Transl Res; 2024 Sep 04; 14(9):2386-2402. PubMed ID: 38236508
    [Abstract] [Full Text] [Related]

  • 16. Development of glycyrrhetinic acid-modified stealth cationic liposomes for gene delivery.
    He ZY, Zheng X, Wu XH, Song XR, He G, Wu WF, Yu S, Mao SJ, Wei YQ.
    Int J Pharm; 2010 Sep 15; 397(1-2):147-54. PubMed ID: 20667672
    [Abstract] [Full Text] [Related]

  • 17. Anti-psoriasis effect of 18β-glycyrrhetinic acid by breaking CCL20/CCR6 axis through its vital active group targeting GUSB/ATF2 signaling.
    Wei J, Zhang J, Hu F, Zhang W, Wu Y, Liu B, Lu Y, Li L, Han L, Lu C.
    Phytomedicine; 2024 Jun 15; 128():155524. PubMed ID: 38552435
    [Abstract] [Full Text] [Related]

  • 18. Development of Glycyrrhetinic Acid and Folate Modified Cantharidin Loaded Solid Lipid Nanoparticles for Targeting Hepatocellular Carcinoma.
    Xu Y, Wang M, Ning S, Yang Z, Zhou L, Xia X.
    Molecules; 2022 Oct 11; 27(20):. PubMed ID: 36296377
    [Abstract] [Full Text] [Related]

  • 19. Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.
    Liu MC, Liu L, Wang XR, Shuai WP, Hu Y, Han M, Gao JQ.
    Int J Nanomedicine; 2016 Oct 11; 11():1395-412. PubMed ID: 27110110
    [Abstract] [Full Text] [Related]

  • 20. Glycyrrhetinic acid-functionalized mesoporous silica nanoparticles as hepatocellular carcinoma-targeted drug carrier.
    Lv Y, Li J, Chen H, Bai Y, Zhang L.
    Int J Nanomedicine; 2017 Oct 11; 12():4361-4370. PubMed ID: 28652738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.